Bio-Techne CFO exercises 62,068 stock options
Bio-Techne Corp CFO James Hippel exercised stock options covering 62,068 shares of common stock on July 29, 2026 at an exercise price of $47.60 per share.
Rhea-AI Filing Summary
Bio-Techne Corp CFO James Hippel exercised stock options covering 62,068 shares of common stock on July 29, 2026 at an exercise price of $47.60 per share. A separate Form 4 entry shows 51,024 shares of common stock disposed of at $72.03 per share, designated as payment of exercise price or tax liability by withholding securities. He continues to hold multiple option and restricted stock unit awards, including options over 167,328 shares at an exercise price of $66.97 expiring August 5, 2027.
Positive
- None.
Negative
- None.
Insider Trade Summary
62,068 shares exercised/converted
Exercise
16 txns
Insider
Hippel James
Role
CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) F1 | 62,068 | $0.00 | $0.00 |
| Exercise | Common Stock | 62,068 | $47.60 | $2.95M |
| Exercise Price or Tax Liability | Common Stock | 51,024 | $72.03 | $3.68M |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F1 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F4 | -- | -- | -- |
| holding | Performance Stock Options (Right to Buy) F4 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F5 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F6 | -- | -- | -- |
| holding | Restricted Stock Units F2, F7 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F8 | -- | -- | -- |
| holding | Restricted Stock Units F2, F9 | -- | -- | -- |
| holding | Performance Restricted Stock Units F2, F10 | -- | -- | -- |
| holding | Restricted Stock Units F2, F11 | -- | -- | -- |
| holding | Stock Options (Right to Buy) F12 | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 369,056 contracts (Direct);
Common Stock — 164,714 shares (Direct);
Performance Restricted Stock Units — 67,347 contracts (Direct);
Performance Stock Options (Right to Buy) — 37,314 contracts (Direct);
Restricted Stock Units — 41,809 contracts (Direct)
Footnotes (12)
- F1. Fully exercisable.
- F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
- F3. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
- F4. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F5. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
- F6. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F7. 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027.
- F8. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
- F9. 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
- F10. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F11. 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
- F12. Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Key Figures
Options exercised: 62068.0000 shares
Option exercise price: 47.6000 per share
Shares withheld for exercise price or taxes: 51024.0000 shares
+4 more
7 metrics
Options exercised
62068.0000 shares
Stock options exercised by CFO James Hippel on 2026-07-29
Option exercise price
47.6000 per share
Exercise price for 62,068 stock options converted into common stock
Shares withheld for exercise price or taxes
51024.0000 shares
Common shares disposed of at $72.03 under code F for payment of exercise price or tax liability
Withholding transaction price
72.0300 per share
Per-share value used for 51,024-share withholding disposition
Remaining options at $66.97
167328.0000 underlying shares
Stock options with $66.9700 exercise price expiring 2027-08-05
Performance stock options at $84.61
37314.0000 underlying shares
Performance stock options expiring 2030-08-15
Restricted Stock Units position
23089.0000 underlying shares
Restricted Stock Units with vesting in 2026 and 2027 per footnote F9
Key Terms
Performance Restricted Stock Units, Restricted Stock Units, Performance Stock Options (Right to Buy), exercise price, +1 more
5 terms
Performance Restricted Stock Units financial
"Security title listed as "Performance Restricted Stock Units" with common stock underlying"
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Restricted Stock Units financial
"Footnote states each restricted stock unit represents a contingent right to one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Stock Options (Right to Buy) financial
"Derivative holding described as "Performance Stock Options (Right to Buy)" with exercise price"
exercise price financial
"Transaction code description references payment of exercise price or tax liability"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
tax liability financial
"Disposition coded F is for payment of exercise price or tax liability by withholding securities"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BIO-TECHNE Corp (TECH) CFO James Hippel report in this Form 4?
CFO James Hippel reported exercising 62,068 stock options for Bio-Techne common stock at an exercise price of $47.60 per share. A related entry shows 51,024 shares disposed of at $72.03 per share as payment of exercise price or tax liability.
How many BIO-TECHNE (TECH) options did the CFO exercise and at what price?
Hippel exercised stock options covering 62,068 shares of Bio-Techne common stock at an exercise price of $47.60 per share. The options were fully exercisable and were scheduled to expire on August 7, 2026 before this exercise.
What BIO-TECHNE (TECH) equity awards does the CFO still hold after this transaction?
Hippel remains entitled to various equity awards, including stock options over 167,328 shares at an exercise price of $66.97 expiring August 5, 2027, plus additional options and restricted stock units and performance units over tens of thousands of Bio-Techne shares.
Are performance-based awards included in the BIO-TECHNE (TECH) CFO’s holdings?
Yes. The holdings include Performance Restricted Stock Units and Performance Stock Options, such as units over 13,865 and 24,062 shares. Related footnotes state these awards vest in full or in part if specified performance goals are achieved by future vesting dates.
Does the BIO-TECHNE (TECH) Form 4 show any remaining restricted stock units for the CFO?
Yes. The filing lists several Restricted Stock Unit positions, including blocks of 4,010, 23,089 and 14,710 underlying shares. Footnotes detail scheduled vesting dates in 2026, 2027 and 2028, each unit converting into one Bio-Techne common share upon vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
